Oskie Capital Management LLC purchased a new position in MetLife, Inc. (NYSE:MET) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 54,000 shares of the financial services provider’s stock, valued at approximately $2,805,000. MetLife comprises about 3.2% of Oskie Capital Management LLC’s holdings, making the stock its 11th biggest position.
Several other large investors also recently modified their holdings of the stock. Bronfman E.L. Rothschild L.P. lifted its holdings in MetLife by 0.7% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,505 shares of the financial services provider’s stock valued at $302,000 after purchasing an additional 38 shares during the last quarter. Forward Management LLC lifted its holdings in MetLife by 0.4% during the second quarter. Forward Management LLC now owns 9,661 shares of the financial services provider’s stock valued at $531,000 after purchasing an additional 41 shares during the last quarter. Aspen Investment Management Inc lifted its holdings in MetLife by 0.7% during the second quarter. Aspen Investment Management Inc now owns 7,178 shares of the financial services provider’s stock valued at $394,000 after purchasing an additional 50 shares during the last quarter. Atria Investments LLC lifted its holdings in MetLife by 0.4% during the second quarter. Atria Investments LLC now owns 18,986 shares of the financial services provider’s stock valued at $1,043,000 after purchasing an additional 72 shares during the last quarter. Finally, Apriem Advisors lifted its holdings in MetLife by 0.6% during the second quarter. Apriem Advisors now owns 13,060 shares of the financial services provider’s stock valued at $718,000 after purchasing an additional 74 shares during the last quarter. 75.85% of the stock is currently owned by institutional investors.
Shares of MetLife, Inc. (NYSE MET) traded up $0.12 during trading on Monday, hitting $51.83. 1,303,100 shares of the stock were exchanged, compared to its average volume of 5,766,896. MetLife, Inc. has a 52-week low of $44.26 and a 52-week high of $55.91. The stock has a market capitalization of $54,540.66, a P/E ratio of 9.97, a price-to-earnings-growth ratio of 1.30 and a beta of 1.51. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.16 and a current ratio of 0.16.
MetLife (NYSE:MET) last announced its quarterly earnings results on Wednesday, November 1st. The financial services provider reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.19. MetLife had a negative net margin of 0.75% and a positive return on equity of 8.81%. The firm had revenue of $16.10 billion for the quarter, compared to the consensus estimate of $15.47 billion. During the same period in the prior year, the firm posted $1.28 earnings per share. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. equities research analysts expect that MetLife, Inc. will post 4.43 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 13th. Stockholders of record on Monday, November 6th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Friday, November 3rd. MetLife’s payout ratio is -320.00%.
Several equities research analysts have commented on MET shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $60.00 price objective (up from $56.00) on shares of MetLife in a report on Friday, November 3rd. Credit Suisse Group reaffirmed a “neutral” rating and set a $53.00 price objective (down from $64.00) on shares of MetLife in a report on Monday, August 28th. Morgan Stanley upped their price objective on shares of MetLife from $54.00 to $55.00 and gave the company an “equal weight” rating in a report on Thursday, October 5th. Sandler O’Neill downgraded shares of MetLife from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Argus dropped their price objective on shares of MetLife from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. MetLife currently has an average rating of “Buy” and an average target price of $58.40.
In other news, insider Christopher G. Townsend sold 55,712 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $54.29, for a total value of $3,024,604.48. Following the sale, the insider now directly owns 25,181 shares of the company’s stock, valued at $1,367,076.49. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher G. Townsend sold 82,731 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $54.60, for a total transaction of $4,517,112.60. Following the completion of the transaction, the insider now owns 49,660 shares in the company, valued at $2,711,436. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.
MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET).
Receive News & Ratings for MetLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.